Not recruiting yet
To Evaluate the Effectiveness and Safety of Single-port Robotic-assisted Subcutaneous Gland Resection Combined With Immediate Breast Reconstruction in Breast Cancer
NCT06706726 · The First Affiliated Hospital with Nanjing Medical University · Updated 29 Nov 2024
- What is being tested
- sentinel lymph node biopsy; Single-port robotic-assisted axillary lymph node dissection
- For
- Breast Cancer
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years to 75 years. About 40 people. The full rules are on the registry page.
- Where
- Not stated
- When
- Starts or started 1 Dec 2024, ends 31 Dec 2028. Registered 27 Nov 2024.
- Results
- None posted yet.
In the researchers' words
The new technology of robotic surgery system, as an emerging technology, has shown certain application prospects in breast surgery. However, the new technology of robotic surgery system in China in the treatment of breast cancer is still in the exploratory stage and needs to be further improved. This prospective, single-center, double-arm clinical study was conducted to use the single-port robot and evaluate the effectiveness and safety of the subcutaneous gland resection combined with immediate breast reconstruction in breast cancer.